Serveur d'exploration sur le lymphœdème

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

The resolution of lymphedema by interstitial flow in the mouse tail skin.

Identifieur interne : 003410 ( PubMed/Curation ); précédent : 003409; suivant : 003411

The resolution of lymphedema by interstitial flow in the mouse tail skin.

Auteurs : Joseph Uzarski [États-Unis] ; Megan B. Drelles ; Sara E. Gibbs ; Emily L. Ongstad ; Julie C. Goral ; Katherine K. Mckeown ; Alisha M. Raehl ; Melissa A. Roberts ; Bronislaw Pytowski ; Martyn R. Smith ; Jeremy Goldman

Source :

RBID : pubmed:18203849

Descripteurs français

English descriptors

Abstract

Lymphangiogenesis is considered a promising approach for increasing fluid drainage during secondary lymphedema. However, organization of lymphatics into functional capillaries may be dependent upon interstitial flow (IF). The present study was undertaken to determine the importance of lymphangiogenesis for lymphedema resolution. We created a lymphatic obstruction that produces lymphedema in mouse tail skin. The relatively scar-free skin regeneration that occurred across the obstruction allowed the progression of lymphangiogenesis to be observed and compared with the evolution of lymphedema. The role of vascular endothelial growth factor-C (VEGF-C)/VEGF receptor (VEGFR)-3 signaling in lymphedema resolution was investigated by exogenous administration of VEGF-C or neutralizing antibodies against VEGFR-3. VEGF-C protein improved lymphedema at 15 days [reducing dermal thickness from 742 +/- 105 to 559 +/- 141 microm with 95% confidence intervals (CIs), P < 0.05] without increasing lymphatic capillary coverage (11.6 +/- 6.4% following VEGF-C treatment relative to 9.6 +/- 6.2% with 95% CIs, P > 0.50). Blocking VEGFR-3 signaling did not inhibit lymphedema resolution at 25 days (dermal thickness of 462 +/- 127 microm following VEGFR-3 inhibition relative to 502 +/- 87 microm with 95% CIs) or inhibit IF, although VEGFR-3 blocking prevented lymphangiogenesis (reducing lymphatic coverage to 0.2 +/- 0.7% relative to 8.7 +/- 7.3% with 95% CIs, P < 0.005). A second mouse tail lymphedema model was employed to investigate the ability of VEGF-C to increase fluid drainage across a scar. We found that neither neutralization of VEGFR-3 nor administration of VEGF-C affected the course of skin swelling over 25 days. These findings suggest that resolution of lymphedema in the mouse tail skin may be more dependent upon IF and regeneration of the extracellular matrix across the obstruction than lymphatic capillary regeneration.

DOI: 10.1152/ajpheart.00900.2007
PubMed: 18203849

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:18203849

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">The resolution of lymphedema by interstitial flow in the mouse tail skin.</title>
<author>
<name sortKey="Uzarski, Joseph" sort="Uzarski, Joseph" uniqKey="Uzarski J" first="Joseph" last="Uzarski">Joseph Uzarski</name>
<affiliation wicri:level="1">
<nlm:affiliation>Biomedical Engineering Department, Michigan Technological University, Houghton, MI 49931, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Biomedical Engineering Department, Michigan Technological University, Houghton, MI 49931</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Drelles, Megan B" sort="Drelles, Megan B" uniqKey="Drelles M" first="Megan B" last="Drelles">Megan B. Drelles</name>
</author>
<author>
<name sortKey="Gibbs, Sara E" sort="Gibbs, Sara E" uniqKey="Gibbs S" first="Sara E" last="Gibbs">Sara E. Gibbs</name>
</author>
<author>
<name sortKey="Ongstad, Emily L" sort="Ongstad, Emily L" uniqKey="Ongstad E" first="Emily L" last="Ongstad">Emily L. Ongstad</name>
</author>
<author>
<name sortKey="Goral, Julie C" sort="Goral, Julie C" uniqKey="Goral J" first="Julie C" last="Goral">Julie C. Goral</name>
</author>
<author>
<name sortKey="Mckeown, Katherine K" sort="Mckeown, Katherine K" uniqKey="Mckeown K" first="Katherine K" last="Mckeown">Katherine K. Mckeown</name>
</author>
<author>
<name sortKey="Raehl, Alisha M" sort="Raehl, Alisha M" uniqKey="Raehl A" first="Alisha M" last="Raehl">Alisha M. Raehl</name>
</author>
<author>
<name sortKey="Roberts, Melissa A" sort="Roberts, Melissa A" uniqKey="Roberts M" first="Melissa A" last="Roberts">Melissa A. Roberts</name>
</author>
<author>
<name sortKey="Pytowski, Bronislaw" sort="Pytowski, Bronislaw" uniqKey="Pytowski B" first="Bronislaw" last="Pytowski">Bronislaw Pytowski</name>
</author>
<author>
<name sortKey="Smith, Martyn R" sort="Smith, Martyn R" uniqKey="Smith M" first="Martyn R" last="Smith">Martyn R. Smith</name>
</author>
<author>
<name sortKey="Goldman, Jeremy" sort="Goldman, Jeremy" uniqKey="Goldman J" first="Jeremy" last="Goldman">Jeremy Goldman</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2008">2008</date>
<idno type="RBID">pubmed:18203849</idno>
<idno type="pmid">18203849</idno>
<idno type="doi">10.1152/ajpheart.00900.2007</idno>
<idno type="wicri:Area/PubMed/Corpus">003410</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003410</idno>
<idno type="wicri:Area/PubMed/Curation">003410</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003410</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">The resolution of lymphedema by interstitial flow in the mouse tail skin.</title>
<author>
<name sortKey="Uzarski, Joseph" sort="Uzarski, Joseph" uniqKey="Uzarski J" first="Joseph" last="Uzarski">Joseph Uzarski</name>
<affiliation wicri:level="1">
<nlm:affiliation>Biomedical Engineering Department, Michigan Technological University, Houghton, MI 49931, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Biomedical Engineering Department, Michigan Technological University, Houghton, MI 49931</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Drelles, Megan B" sort="Drelles, Megan B" uniqKey="Drelles M" first="Megan B" last="Drelles">Megan B. Drelles</name>
</author>
<author>
<name sortKey="Gibbs, Sara E" sort="Gibbs, Sara E" uniqKey="Gibbs S" first="Sara E" last="Gibbs">Sara E. Gibbs</name>
</author>
<author>
<name sortKey="Ongstad, Emily L" sort="Ongstad, Emily L" uniqKey="Ongstad E" first="Emily L" last="Ongstad">Emily L. Ongstad</name>
</author>
<author>
<name sortKey="Goral, Julie C" sort="Goral, Julie C" uniqKey="Goral J" first="Julie C" last="Goral">Julie C. Goral</name>
</author>
<author>
<name sortKey="Mckeown, Katherine K" sort="Mckeown, Katherine K" uniqKey="Mckeown K" first="Katherine K" last="Mckeown">Katherine K. Mckeown</name>
</author>
<author>
<name sortKey="Raehl, Alisha M" sort="Raehl, Alisha M" uniqKey="Raehl A" first="Alisha M" last="Raehl">Alisha M. Raehl</name>
</author>
<author>
<name sortKey="Roberts, Melissa A" sort="Roberts, Melissa A" uniqKey="Roberts M" first="Melissa A" last="Roberts">Melissa A. Roberts</name>
</author>
<author>
<name sortKey="Pytowski, Bronislaw" sort="Pytowski, Bronislaw" uniqKey="Pytowski B" first="Bronislaw" last="Pytowski">Bronislaw Pytowski</name>
</author>
<author>
<name sortKey="Smith, Martyn R" sort="Smith, Martyn R" uniqKey="Smith M" first="Martyn R" last="Smith">Martyn R. Smith</name>
</author>
<author>
<name sortKey="Goldman, Jeremy" sort="Goldman, Jeremy" uniqKey="Goldman J" first="Jeremy" last="Goldman">Jeremy Goldman</name>
</author>
</analytic>
<series>
<title level="j">American journal of physiology. Heart and circulatory physiology</title>
<idno type="ISSN">0363-6135</idno>
<imprint>
<date when="2008" type="published">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Animals</term>
<term>Antibodies, Blocking (pharmacology)</term>
<term>Extracellular Fluid (physiology)</term>
<term>Female</term>
<term>Fluorescent Antibody Technique</term>
<term>Immunohistochemistry</term>
<term>Lymphangiogenesis (physiology)</term>
<term>Lymphedema (pathology)</term>
<term>Lymphedema (physiopathology)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Receptors, Vascular Endothelial Growth Factor (antagonists & inhibitors)</term>
<term>Receptors, Vascular Endothelial Growth Factor (metabolism)</term>
<term>Regeneration</term>
<term>Skin (pathology)</term>
<term>Skin (physiopathology)</term>
<term>Tail</term>
<term>Vascular Endothelial Growth Factor A (metabolism)</term>
<term>Vascular Endothelial Growth Factor A (pharmacology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Animaux</term>
<term>Anticorps bloquants (pharmacologie)</term>
<term>Facteur de croissance endothéliale vasculaire de type A (métabolisme)</term>
<term>Facteur de croissance endothéliale vasculaire de type A (pharmacologie)</term>
<term>Femelle</term>
<term>Immunohistochimie</term>
<term>Liquide extracellulaire (physiologie)</term>
<term>Lymphangiogenèse (physiologie)</term>
<term>Lymphoedème (anatomopathologie)</term>
<term>Lymphoedème (physiopathologie)</term>
<term>Peau (anatomopathologie)</term>
<term>Peau (physiopathologie)</term>
<term>Queue</term>
<term>Récepteurs aux facteurs de croissance endothéliale vasculaire (antagonistes et inhibiteurs)</term>
<term>Récepteurs aux facteurs de croissance endothéliale vasculaire (métabolisme)</term>
<term>Régénération</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Technique d'immunofluorescence</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en">
<term>Receptors, Vascular Endothelial Growth Factor</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Receptors, Vascular Endothelial Growth Factor</term>
<term>Vascular Endothelial Growth Factor A</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Antibodies, Blocking</term>
<term>Vascular Endothelial Growth Factor A</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr">
<term>Lymphoedème</term>
<term>Peau</term>
</keywords>
<keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr">
<term>Récepteurs aux facteurs de croissance endothéliale vasculaire</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr">
<term>Facteur de croissance endothéliale vasculaire de type A</term>
<term>Récepteurs aux facteurs de croissance endothéliale vasculaire</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Lymphedema</term>
<term>Skin</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Anticorps bloquants</term>
<term>Facteur de croissance endothéliale vasculaire de type A</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr">
<term>Liquide extracellulaire</term>
<term>Lymphangiogenèse</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en">
<term>Extracellular Fluid</term>
<term>Lymphangiogenesis</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr">
<term>Lymphoedème</term>
<term>Peau</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en">
<term>Lymphedema</term>
<term>Skin</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Animals</term>
<term>Female</term>
<term>Fluorescent Antibody Technique</term>
<term>Immunohistochemistry</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Regeneration</term>
<term>Tail</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Animaux</term>
<term>Femelle</term>
<term>Immunohistochimie</term>
<term>Queue</term>
<term>Régénération</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Technique d'immunofluorescence</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Lymphangiogenesis is considered a promising approach for increasing fluid drainage during secondary lymphedema. However, organization of lymphatics into functional capillaries may be dependent upon interstitial flow (IF). The present study was undertaken to determine the importance of lymphangiogenesis for lymphedema resolution. We created a lymphatic obstruction that produces lymphedema in mouse tail skin. The relatively scar-free skin regeneration that occurred across the obstruction allowed the progression of lymphangiogenesis to be observed and compared with the evolution of lymphedema. The role of vascular endothelial growth factor-C (VEGF-C)/VEGF receptor (VEGFR)-3 signaling in lymphedema resolution was investigated by exogenous administration of VEGF-C or neutralizing antibodies against VEGFR-3. VEGF-C protein improved lymphedema at 15 days [reducing dermal thickness from 742 +/- 105 to 559 +/- 141 microm with 95% confidence intervals (CIs), P < 0.05] without increasing lymphatic capillary coverage (11.6 +/- 6.4% following VEGF-C treatment relative to 9.6 +/- 6.2% with 95% CIs, P > 0.50). Blocking VEGFR-3 signaling did not inhibit lymphedema resolution at 25 days (dermal thickness of 462 +/- 127 microm following VEGFR-3 inhibition relative to 502 +/- 87 microm with 95% CIs) or inhibit IF, although VEGFR-3 blocking prevented lymphangiogenesis (reducing lymphatic coverage to 0.2 +/- 0.7% relative to 8.7 +/- 7.3% with 95% CIs, P < 0.005). A second mouse tail lymphedema model was employed to investigate the ability of VEGF-C to increase fluid drainage across a scar. We found that neither neutralization of VEGFR-3 nor administration of VEGF-C affected the course of skin swelling over 25 days. These findings suggest that resolution of lymphedema in the mouse tail skin may be more dependent upon IF and regeneration of the extracellular matrix across the obstruction than lymphatic capillary regeneration.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">18203849</PMID>
<DateCreated>
<Year>2008</Year>
<Month>03</Month>
<Day>07</Day>
</DateCreated>
<DateCompleted>
<Year>2008</Year>
<Month>05</Month>
<Day>15</Day>
</DateCompleted>
<DateRevised>
<Year>2009</Year>
<Month>11</Month>
<Day>19</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Print">0363-6135</ISSN>
<JournalIssue CitedMedium="Print">
<Volume>294</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2008</Year>
<Month>Mar</Month>
</PubDate>
</JournalIssue>
<Title>American journal of physiology. Heart and circulatory physiology</Title>
<ISOAbbreviation>Am. J. Physiol. Heart Circ. Physiol.</ISOAbbreviation>
</Journal>
<ArticleTitle>The resolution of lymphedema by interstitial flow in the mouse tail skin.</ArticleTitle>
<Pagination>
<MedlinePgn>H1326-34</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1152/ajpheart.00900.2007</ELocationID>
<Abstract>
<AbstractText>Lymphangiogenesis is considered a promising approach for increasing fluid drainage during secondary lymphedema. However, organization of lymphatics into functional capillaries may be dependent upon interstitial flow (IF). The present study was undertaken to determine the importance of lymphangiogenesis for lymphedema resolution. We created a lymphatic obstruction that produces lymphedema in mouse tail skin. The relatively scar-free skin regeneration that occurred across the obstruction allowed the progression of lymphangiogenesis to be observed and compared with the evolution of lymphedema. The role of vascular endothelial growth factor-C (VEGF-C)/VEGF receptor (VEGFR)-3 signaling in lymphedema resolution was investigated by exogenous administration of VEGF-C or neutralizing antibodies against VEGFR-3. VEGF-C protein improved lymphedema at 15 days [reducing dermal thickness from 742 +/- 105 to 559 +/- 141 microm with 95% confidence intervals (CIs), P < 0.05] without increasing lymphatic capillary coverage (11.6 +/- 6.4% following VEGF-C treatment relative to 9.6 +/- 6.2% with 95% CIs, P > 0.50). Blocking VEGFR-3 signaling did not inhibit lymphedema resolution at 25 days (dermal thickness of 462 +/- 127 microm following VEGFR-3 inhibition relative to 502 +/- 87 microm with 95% CIs) or inhibit IF, although VEGFR-3 blocking prevented lymphangiogenesis (reducing lymphatic coverage to 0.2 +/- 0.7% relative to 8.7 +/- 7.3% with 95% CIs, P < 0.005). A second mouse tail lymphedema model was employed to investigate the ability of VEGF-C to increase fluid drainage across a scar. We found that neither neutralization of VEGFR-3 nor administration of VEGF-C affected the course of skin swelling over 25 days. These findings suggest that resolution of lymphedema in the mouse tail skin may be more dependent upon IF and regeneration of the extracellular matrix across the obstruction than lymphatic capillary regeneration.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Uzarski</LastName>
<ForeName>Joseph</ForeName>
<Initials>J</Initials>
<AffiliationInfo>
<Affiliation>Biomedical Engineering Department, Michigan Technological University, Houghton, MI 49931, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Drelles</LastName>
<ForeName>Megan B</ForeName>
<Initials>MB</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gibbs</LastName>
<ForeName>Sara E</ForeName>
<Initials>SE</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Ongstad</LastName>
<ForeName>Emily L</ForeName>
<Initials>EL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Goral</LastName>
<ForeName>Julie C</ForeName>
<Initials>JC</Initials>
</Author>
<Author ValidYN="Y">
<LastName>McKeown</LastName>
<ForeName>Katherine K</ForeName>
<Initials>KK</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Raehl</LastName>
<ForeName>Alisha M</ForeName>
<Initials>AM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Roberts</LastName>
<ForeName>Melissa A</ForeName>
<Initials>MA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Pytowski</LastName>
<ForeName>Bronislaw</ForeName>
<Initials>B</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Smith</LastName>
<ForeName>Martyn R</ForeName>
<Initials>MR</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Goldman</LastName>
<ForeName>Jeremy</ForeName>
<Initials>J</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>1R15HL-081102</GrantID>
<Acronym>HL</Acronym>
<Agency>NHLBI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>1R21AR-053094</GrantID>
<Acronym>AR</Acronym>
<Agency>NIAMS NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2008</Year>
<Month>01</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Am J Physiol Heart Circ Physiol</MedlineTA>
<NlmUniqueID>100901228</NlmUniqueID>
<ISSNLinking>0363-6135</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019138">Antibodies, Blocking</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D042461">Vascular Endothelial Growth Factor A</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>EC 2.7.10.1</RegistryNumber>
<NameOfSubstance UI="D040262">Receptors, Vascular Endothelial Growth Factor</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D019138" MajorTopicYN="N">Antibodies, Blocking</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D045604" MajorTopicYN="N">Extracellular Fluid</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005455" MajorTopicYN="N">Fluorescent Antibody Technique</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D042583" MajorTopicYN="N">Lymphangiogenesis</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D040262" MajorTopicYN="N">Receptors, Vascular Endothelial Growth Factor</DescriptorName>
<QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012038" MajorTopicYN="N">Regeneration</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012867" MajorTopicYN="N">Skin</DescriptorName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013623" MajorTopicYN="N">Tail</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D042461" MajorTopicYN="N">Vascular Endothelial Growth Factor A</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="pubmed">
<Year>2008</Year>
<Month>1</Month>
<Day>22</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2008</Year>
<Month>5</Month>
<Day>16</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2008</Year>
<Month>1</Month>
<Day>22</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">18203849</ArticleId>
<ArticleId IdType="pii">00900.2007</ArticleId>
<ArticleId IdType="doi">10.1152/ajpheart.00900.2007</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003410 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003410 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:18203849
   |texte=   The resolution of lymphedema by interstitial flow in the mouse tail skin.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:18203849" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1 

Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024